Alexion Not Scared Of Amgen Biosimilar Threat To Soliris
Companies Settled Eculizumab Litigation In US Earlier This Year
Executive Summary
Alexion Pharmaceuticals is confident of its strategy to switch patients from Soliris to Ultomiris as the threat of biosimilar competition to the former looms. But launching a biosimilar to Soliris alone will be a challenge, the company maintains.
You may also be interested in...
Amgen Chooses To Settle In US Soliris IPR Tussle
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
Inflexion Outlines Rosemont Investment And Eyes More Generics Deals
In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.
Mylan Symbicort Trial Looms As Company Eyes First US Generic
A trial will begin next month in Mylan’s bid to overcome patents shielding AstraZeneca’s Symbicort respiratory brand in the US. With rival Teva having previously settled ANDA action, Mylan is in the driving seat for a first substitutable generic.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: